Woodline Partners LP Uro Gen Pharma Ltd. Transaction History
Woodline Partners LP
- $19.5 Billion
- Q3 2025
A detailed history of Woodline Partners LP transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Woodline Partners LP holds 306,371 shares of URGN stock, worth $7.45 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
306,371
Previous 306,724
0.12%
Holding current value
$7.45 Million
Previous $4.2 Million
42.31%
% of portfolio
0.03%
Previous 0.02%
Shares
5 transactions
Others Institutions Holding URGN
# of Institutions
171Shares Held
43.8MCall Options Held
1.61MPut Options Held
433K-
Rtw Investments, LP New York, NY4.54MShares$111 Million1.19% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY4.22MShares$103 Million2.65% of portfolio
-
Toronto Dominion Bank Toronto, Ontario, A63.19MShares$77.6 Million0.1% of portfolio
-
Morgan Stanley New York, NY2.53MShares$61.5 Million0.0% of portfolio
-
Jefferies Financial Group Inc. New York, NY2.2MShares$53.5 Million0.21% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $553M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...